SCHEMBL23978009

SCHEMBL23978009

Cc1cc(S(C)(=O)=O)cc(C(=O)O)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.41
HIF1A Q16665 1/20 0.41
LMNA P02545 3/20 0.39
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GPR35 Q9HC97 2/20 0.38
TDP1 Q9NUW8 1/20 0.36
PTGS2 P35354 1/20 0.35
AKR1C3 P42330 2/20 0.35
AKR1C2 P52895 2/20 0.35
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28042691 0.88 ALOX15 (0.52) DAOHCAR2TSHRALOX15HIF1A
SCHEMBL4777636 0.77 GRK6 (0.44)
SCHEMBL21200998 0.75 CBLB (0.43) DAOHCAR2TSHRALOX15HIF1A
SCHEMBL668136 0.74 ALOX15 (0.48) DAOHCAR2TSHRALOX15HIF1A
SCHEMBL3686639 0.72 ALOX15 (0.71) DAOHCAR2TSHRALOX15HIF1A
SCHEMBL4772052 0.72 ALOX15 (0.46) DAOHCAR2TSHRALOX15HIF1A
SCHEMBL9507755 0.72 ALOX15 (0.46) DAOHCAR2TSHRALOX15HIF1A
SCHEMBL1424923 0.71 ALDH1A1 (0.47) DAOHCAR2TSHRALOX15HIF1A
SCHEMBL21440816 0.71 ALOX15 (0.45) DAOHCAR2TSHRALOX15HIF1A
SCHEMBL31336152 0.71 ALDH1A1 (0.47) DAOHCAR2TSHRALOX15HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739685-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008061-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED 2021-11-11 US disclosed
WO-2021222174-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS INCORPORATED (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346405-A1 BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS BCL2, BCL2L2, BCL2L1 DAO 4443/4885HCAR2 2799/4885TSHR 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.